$27.95
-0.75-2.6%
Last update: Nov 12, 2:48 PM
Zenas BioPharma Inc
ZBIONASDAQ
Zenas BioPharma fell 19.8% from $35.80 to $28.70, behind the S&P 500's +11.2%. Its worst day was Jan 5 (−51.9%), and its low came Jan 6 at $15.20.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.22 missed the $-0.98 estimate on $0.00 revenue (est. $2.8M).
0.0% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE.In the Phase 2b study of orelabrutinib, a total of 187 patients were enrolled and randomized
−19.7% · S&P 500 −0.2%
Zenas BioPharma closed at its highest level of the year, 20.6% above where the year started.
+0.8% · S&P 500 +0.4%
Zenas BioPharma closed at its lowest level of the year, 57.5% below where the year started.
−8.5% · S&P 500 +0.6%
EPS of $-4.54 was reported on $0.00 revenue.
−3.4% · S&P 500 +1.0%
Zenas BioPharma shares fell 17.8%, while the S&P 500 fell 1.7%.
−17.8% · S&P 500 −1.7%
EPS of $-1.46 beat the $-1.54 estimate on $0.00 revenue.
+4.0% · S&P 500 +0.6%
EPS of $-1.77 missed the $-0.78 estimate on $1.0M revenue (est. $27.0M).
−6.7% · S&P 500 +0.7%
EPS of $-1.65 missed the $-1.26 estimate on $10.0M revenue.
−8.9% · S&P 500 −4.4%
Where it ended: a close of $28.70 on Nov 11, 2026.
Nothing in the past 12 months.
All ZBIO dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ZBIO and SPY from Benzinga historical bars. Not investment advice.
